HENLIUS (02696): FULINNING® (Fulvestrant Citrate Capsules) Included in China's National Reimbursement Drug List

Stock News

Dec 07

HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have progressed after prior endocrine therapy. The updated NRDL will take effect on January 1, 2026.

FULINNING® is an innovative CDK4/6 small molecule inhibitor licensed by the company. It was first approved in China in May 2025 for the above-mentioned indication. In September 2025, an additional indication was approved for FULINNING® in China, allowing its use in combination with aromatase inhibitors as initial endocrine therapy for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1129047194"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129047194\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129047194?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129047194","market":"us","top_or_hot":-1,"title":"HENLIUS (02696): FULINNING® (Fulvestrant Citrate Capsules) Included in China's National Reimbursement Drug List","media":"Stock News","content":"<p>HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have progressed after prior endocrine therapy. The updated NRDL will take effect on January 1, 2026.</p>\n<p>FULINNING® is an innovative CDK4/6 small molecule inhibitor licensed by the company. It was first approved in China in May 2025 for the above-mentioned indication. In September 2025, an additional indication was approved for FULINNING® in China, allowing its use in combination with aromatase inhibitors as initial endocrine therapy for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS (02696): FULINNING® (Fulvestrant Citrate Capsules) Included in China's National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS (02696): FULINNING® (Fulvestrant Citrate Capsules) Included in China's National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-07 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have progressed after prior endocrine therapy. The updated NRDL will take effect on January 1, 2026.</p>\n<p>FULINNING® is an innovative CDK4/6 small molecule inhibitor licensed by the company. It was first approved in China in May 2025 for the above-mentioned indication. In September 2025, an additional indication was approved for FULINNING® in China, allowing its use in combination with aromatase inhibitors as initial endocrine therapy for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000165453.HKD","symbol_name":"华夏精选大中华科技基金 A类港币","start_time":0,"source_url":"","article_id":"1129047194","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129047194","pubTimestamp":1765104168,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","02696":"复宏汉霖","BK1161":"生物科技"},"translate_title":"复宏汉霖(02696)：福林宁®（枸橼酸氟维司群胶囊）纳入中国国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have progressed after prior endocrine therapy. The updated NRDL will take effect on January 1, 2026.\nFULINNING® is an innovative CDK4/6 small molecule inhibitor licensed by the company. It was first approved in China in May 2025 for the above-mentioned indication. In September 2025, an additional indication was approved for FULINNING® in China, allowing its use in combination with aromatase inhibitors as initial endocrine therapy for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}